Computer-aided design of aptamers for cytochrome p450

Journal of Structural Biology

Volumn 191, Issue 2, 2015, Pages 112-119

  Shcherbinin, Dmitrii S ^a   Gnedenko, Oksana V ^a   Khmeleva, Svetlana A ^a   Usanov, Sergey A ^b   Gilep, Andrei A ^b   Yantsevich, Aliaksei V ^b   Shkel, Tatsiana V ^b   Yushkevich, Ivan V ^b   Radko, Sergey P ^a   Ivanov, Alexis S ^a   Veselovsky, Alexander V ^a   Archakov, Alexander I ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^b INSTITUTE OF BIOORGANIC CHEMISTRY   (Belarus)

Author keywords

Aptamer; Bioinformatics; Cytochrome P450 51A1; Molecular docking; Molecular dynamics; Rational design; SELEX

Indexed keywords

APTAMER; PROTEIN CYTOCHROME P450 51A1; STEROL 14ALPHA DEMETHYLASE; UNCLASSIFIED DRUG; CYTOCHROME P450;

ARTICLE; BINDING AFFINITY; BINDING SITE; BIOSENSOR; COMPUTER AIDED DESIGN; COMPUTER MODEL; EXPERIMENTAL DESIGN; HUMAN; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; PROCEDURES; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

APTAMERS, NUCLEOTIDE; BINDING SITES; CYTOCHROME P-450 ENZYME SYSTEM; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; NUCLEIC ACID CONFORMATION; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84937813386     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2015.07.003     Document Type: Article

References (48)

1. Ahmad K.M., Oh S.S., Kim S., McClellen F.M., Xiao Y., Soh H.T. Probing the limits of aptamer affinity with a microfluidic SELEX platform. PLoS One 2011, 6:27051.
2. Ahuja S., Jahr N., Im S.C., Vivekanandan S., Popovych N., Le Clair S.V., Huang R., Soong R., Xu J., Yamamoto K., Nanga R.P., Bridges A., Waskell L., Ramamoorthy A. A model of the membrane-bound cytochrome b5-cytochrome P450 complex from NMR and mutagenesis data. J. Biol. Chem. 2013, 288:22080-22095.
3. Baldrich E., Zourob M. Aptamers: versatile tools for reagentless aptasensing. Recognit. Receptors Biosens. 2010, 675-772. Chap. 17.
4. Balogh Z., Lautner G., Bardyczy V., Komorowska B., Gyurcsányi R.E., Mészáros T. Selection and versatile application of virus-specific aptamers. FASEB J. 2010, 24:4187-4195.
5. Barcellos G.B., Pauli I., Caceres R.A., Timmers L.F., Dias R., de Azevedo W.F. Molecular modeling as a tool for drug discovery. Curr. Drug Targets 2008, 9:1084-1091.
6. Berezovski M., Nutiu R., Li Y., Krylov S.N. Affinity analysis of a protein-aptamer complex using nonequilibrium capillary electrophoresis of equilibrium mixtures. Anal. Chem. 2003, 75:1382.
7. Bridges A., Gruenke L., Chang Y.T., Vakser I.A., Loew G., Waskell L. Identification of the binding site on cytochrome P450 2B4 for cytochrome b5 and cytochrome P450 reductase. J. Biol. Chem. 1998, 273:17036-1704.
8. Case D.A., Darden T.A., Cheatham T.E., Simmerling C.L., Wang J., Duke R.E., Luo R., Merz K.M., Pearlman D.A., Crowley M., Walker R.C., Zhang W., Wang B., Hayik S., Roitberg A., Seabra G., Wong K.F., Paesani F., Wu X., Brozell S., Tsui V., Gohlke H., Yang L., Tan C., Mongan J., Hornak V., Cui G., Beroza P., Mathews D.H., Schafmeister C., Ross W.S., Kollman P.A. AMBER 9 2006, University of California, San Francisco.
9. Chudaev M.V., Gilep A.A., Usanov S.A. Site-directed mutagenesis of cytochrome b5 for studies of its interaction with cytochrome P450. Biochemistry (Mosc.) 2001, 66:667-681.
10. Chushak Y., Stone M.O. In silico selection of RNA aptamers. Nucleic Acids Res. 2009, 37:87.
11. Citartan M., Gopinath S.C., Tominaga J., Tan S.C., Tang T.H. Assays for aptamer-based platforms. Biosens. Bioelectron. 2012, 34:1-11.
12. Connor A.C., McGown L.B. Aptamer stationary phase for protein capture in affinity capillary chromatography. J. Chromatogr. A 2006, 1111:115-119.
13. Dailey M.M., Hait C., Holt P.A., Maguire J.M., Meier J.B., Miller M.C., Petraccone L., Trent J.O. Structure-based drug design: from nucleic acid to membrane protein targets. Exp. Mol. Pathol. 2009, 86:141-150.
14. Davis K.A., Lin Y., Abrams B., Jayasena S.D. Staining of cell surface human CD4 with 2'-F-pyrimidine-containing RNA aptamers for flow cytometry. Nucleic Acids Res. 1998, 26:3915-3924.
15. Deng Q., German I., Buchanan D., Kennedy R.T. Retention and separation of adenosine and analogues by affinity chromatography with an aptamer stationary phase. Anal. Chem. 2001, 73:5415-5421.
16. Dey B., Thukral S., Krishnan S., Chakrobarty M., Gupta S., Manghani C., Rani V. DNA-protein interactions: methods for detection and analysis. Mol. Cell. Biochem. 2012, 365(1-2):279-299.
17. Ferreira C.S., Papamichael K., Guilbault G., Schwarzacher T., Gariepy J., Missailidis S. DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody sandwich ELISA for the early diagnosis of epithelial tumours. Anal. Bioanal. Chem. 2008, 390:1039.
18. German I., Buchanan D.D., Kennedy R.T. Aptamers as ligands in affinity probe capillary electrophoresis. Anal. Chem. 1998, 70:4540-4545.
19. Gnedenko O.V., Kaluzhskiy L.A., Molnar A.A., Yantsevich A.V., Mukha D.V., Gilep A.A., Usanov S.A., Stonik V.A., Ivanov A.S., Lisitsa A.V., Archakov A.I. The SPR-based biosensor test system for analysis of small compounds interaction with human cytochrome P450 51A1 (CYP51A1). Biochem. (Mosc.) Suppl. B: Biomed. Chem. 2013, 7:187-195.
20. Guryev O.L., Gilep A.A., Usanov S.A., Estabrook R.W. Interaction of apo-cytochrome b5 with cytochromes P4503A4 and P45017A: relevance of heme transfer reactions. Biochemistry 2001, 40:5018-5031.
21. Humphrey W., Dalke A., Schulten K. VMD - Visual Molecular Dynamics. J. Mol. Graphics 1996, 14:33-38.
22. Ivanov A.S., Gnedenko O.V., Molnar A.A., Archakov A.I., Podust L.M. FMN binding site of yeast NADPH-cytochrome P450 reductase exposed at the surface is highly specific. ACS Chem. Biol. 2010, 20:767-776.
23. Joseph-McCarthy D., Campbell A.J., Kern G., Moustakas D. Fragment-based lead discovery and design. J. Chem. Inf. Model. 2014, 54(3):693-704.
24. Kanwar J.R., Roy K., Kanwar R.K. Chimeric aptamers in cancer cell-targeted drug delivery. Crit. Rev. Biochem. Mol. Biol. 2011, 46:459-477.
25. Keefe A.D., Schaub R.G. Aptamers as candidate therapeutics for cardiovascular indications. Curr. Opin. Pharmacol. 2008, 8:147-152.
26. Kumar A., Voet A., Zhang K.Y. Fragment based drug design: from experimental to computational approaches. Curr. Med. Chem. 2012, 9(30):5128-5147.
27. Lang P.T., Brozell S.R., Mukherjee S., Pettersen E.F., Meng E.C., Thomas V., Rizzo R.C., Case D.A., James T.L., Kuntz I.D. DOCK 6: combining techniques to model RNA-small molecule complexes. RNA 2009, 15:1219-1230.
28. Lepesheva G.I., Waterman M.R. CYP51 - the omnipotent P450. Mol. Cell. Endocrinol. 2004, 215:165-170.
29. Ma B., Wolfson H.J., Nussinov R. Protein functional epitopes: hot spots, dynamics and combinatorial libraries. Curr. Opin. Struct. Biol. 2001, 11:364-369.
30. Ma D.L., Chan D.S., Lee P., Kwan M.H., Leung C.H. Molecular modeling of drug-DNA interactions: virtual screening to structure-based design. Biochimie 2011, 93:1252-1266.
31. Mayer G. The chemical biology of aptamers. Angew Chem. Int. Ed. Eng. 2009, 48:2672-2689.
32. Moreira I.S., Fernandes P.A., Ramos M.J. Hot spots - a review of the protein-protein interface determinant amino-acid residues. Proteins 2007, 68:803-812.
33. Mukha D.V., Feranchuk S.I., Gilep A.A., Usanov S.A. Molecular modeling of human lanosterol 14α-demethylase complexes with substrates and their derivatives. Biochemistry (Mosc.) 2011, 76:175-185.
34. Muller J., Wulffen B., Potzch B., Mayer G. Multidomain targeting generates a high-affinity thrombin-inhibiting bivalent aptamer. ChemBioChem 2007, 8:2223-2226.
35. Ng E.W., Shima D.T., Calias P., Cunningham E.T., Guyer D.R., Adamis A.P., Pegaptanib A targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 2006, 52:123-132.
36. Ni X., Castanares M., Mukherjee A., Lupold S.E. Nucleic acid aptamers: clinical applications and promising new horizons. Curr. Med. Chem. 2011, 18:4206-4214.
37. Padmanabhan K., Tulinsky A. An ambiguous structure of a DNA 15-mer thrombin complex. Acta Crystallogr. 1996, 52:272-282.
38. Rakhmetova S.Yu., Radko S.P., Gnedenko O.V., Bodoev N.V., Ivanov A.S., Archakov A.I. Comparative thermodynamic analysis of thrombin interaction with anti-thrombin aptamers and their heterodimeric construct. Biochem. (Mosc.) Suppl. B: Biomed. Chem. 2011, 5:139-143.
39. Sa-Debeljak N., Fink M., Rozman D. Many facets of mammalian lanosterol 14a-demethylase from the evolutionarily conserved cytochrome P450 family CYP51. Arch. Biochem. Biophys. 2003, 409:159-171.
40. Sanchez I.E., Ferreiro D.U., Dellarole M., de Prat-Gay G. Experimental snapshots of a protein-DNA binding landscape. PNAS 2010, 107:7751-7756.
41. Sefah K., Shangguan D., Xiong X., O'Donoghue M.B., Tan W. Development of DNA aptamers using Cell-SELEX. Nat. Protoc. 2010, 5:1169-1185.
42. Shcherbinin D.S., Veselovsky A.V. Investigation of interaction of thrombin-binding aptamer with thrombin and prethrombin-2 by simulation of molecular dynamics. Biophysics 2013, 58:315-323.
43. Stoltenburg R., Reinemann C., Strehlitz B. SELEX - a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol. Eng. 2007, 24:381-403.
44. Strushkevich N., Usanov S.A., Park H.W. Structural basis of human CYP51 inhibition by antifungal azoles. J. Mol. Biol. 2010, 397:1067-1078.
45. Tombelli S., Minunni M., Luzi E., Mascini M. Aptamer-based biosensors for the detection of HIV-1 Tat protein. Bioelectrochemistry 2005, 67:135-141.
46. Ulrich H., Trujillo C.A., Nery A.A., Alves J.M., Majumder P., Resende R.R., Martins A.H. DNA and RNA aptamers: from tools for basic research towards therapeutic applications. Comb. Chem. High Throughput Screen. 2006, 9:619-632.
47. Veselovsky A.V., Archakov A.I. Inhibitors of Protein-Protein Interactions as Potential Drugs. Curr. Comput. Aided Drug Des. 2007, 3:51-58.
48. Waterman M.R., Lepesheva G.I. Sterol 14 alpha-demethylase, an abundant and essential mixed-function oxidase. Biochem. Biophys. Res. Commun. 2005, 338:418-422.